HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Spinal Injuries (Spinal Injury)

Injuries involving the vertebral column.
Also Known As:
Spinal Injury; Injuries, Spinal; Injury, Spinal
Networked: 555 relevant articles (19 outcomes, 64 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Spinal Cord Injuries (Spinal Cord Injury)
2. Pain (Aches)
3. Infection
4. Ischemia
5. Quadriplegia (Locked In Syndrome)

Experts

1. Nistri, A: 5 articles (09/2011 - 01/2005)
2. Murray, Marion: 4 articles (10/2005 - 10/2002)
3. Shiba, Keiichiro: 3 articles (11/2015 - 09/2004)
4. Ueta, Takayoshi: 3 articles (11/2015 - 09/2004)
5. Scivoletto, Giorgio: 3 articles (06/2015 - 03/2004)
6. Shen, Xiongjie: 3 articles (01/2015 - 06/2013)
7. Mitchell, Gordon S: 3 articles (12/2014 - 01/2004)
8. Marsala, Martin: 3 articles (10/2013 - 07/2006)
9. Vaidyanathan, Subramanian: 3 articles (01/2012 - 01/2006)
10. Nistri, Andrea: 3 articles (06/2011 - 01/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Spinal Injuries:
1. Naloxone (Narcan)FDA LinkGeneric
2. Thyrotropin-Releasing Hormone (Protirelin)FDA Link
3. Enoxaparin (Lovenox)FDA LinkGeneric
4. Cimetidine (Biomet)FDA LinkGeneric
5. FleroxacinIBA
6. Ciprofloxacin (Cipro)FDA LinkGeneric
7. Substance PIBA
8. Dopamine (Intropin)FDA LinkGeneric
9. Bupivacaine (Bupivacaine Hydrochloride)FDA LinkGeneric
10. Small Interfering RNA (siRNA)IBA

Therapies and Procedures

1. Transplants (Transplant)
2. Transplantation (Transplant Recipients)
08/01/1994 - "4. More controlled animal studies are needed (a) to demonstrate efficacy and to evaluate the necessity for immunosuppressive therapy and the overall safety of intraspinal transplantation, (b) to obtain more supporting evidence (e.g., electrophysiologic, histopathologic, MRI, molecular) that would provide insights into ways that transplanted tissue could mediate function, (c) to provide guidance for the procurement, harvesting, preparation, storage, and other logistics related to the use of human cells for transplantation into the spinal cord, (d) to define more thoroughly the cell type(s) that would be most likely to have benefit and the conditions that affect their viability, migration, gene expressions, and proliferation after transplantation, (e) to determine the most optimal time after injury for transplantation, and (f) to clarify patient selection characteristics that might optimize success (i.e., complete vs incomplete injuries, spinal level involved, age of recipient)."
01/01/2014 - "Thus, transplantation of olfactory ensheathing cells promoted spinal and neurofunctional recovery in patients with malignant spinal injuries, and this therapeutic method was safe. "
05/01/2013 - "These results suggested transplantation of CD34(+) HUCBCs during the acute phase could promote the functional recovery better than during the subacute phase after SCI by raising blood vessel density, suggesting the possible clinical application for the treatment of spinal injury."
01/01/2012 - "Motor and sensitive improvements were evaluated by means of American Spinal Injury Association (ASIA) grading and Functional Independence Measure (FIM); bladder and urethral function were determined by clinical and urodynamic examination; somatosensory evoked potentials (SSEPs) and motor evoked potentials (MEPs) were used to further confirm the functional recovery following transplantation. "
01/01/2012 - "The recovery of American Spinal Injury Association Impairment Scale (AIS) B and C patients at transplantation was rapid and remarkable, but gradual or limited in AIS A patients. "
3. Autologous Transplantation
4. Length of Stay
06/01/2015 - "Demographic characteristics (eg, age, sex), time frame over which clinical symptoms of spinal cord dysfunction developed, etiology, length of stay in hospital, level of lesion and American Spinal Injury Association Impairment Scale (AIS) grade, discharge destination, and inpatient mortality. "
09/01/2014 - "Trajectories are based on relationships between growth parameters and patient and injury factors: race, gender, level of education at admission, age at injury, neurological level at discharge, American Spinal Injury Association Impairment Scale (AIS) at discharge, days from injury to first system inpatient rehabilitation admission, rehabilitation length of stay, marital status and etiology. "
07/01/2014 - "Neurologic deterioration, disposition from the emergency department, in-hospital mortality, interfacility transfer time, hospital length of stay, nonroutine discharge, and radiographic evidence of worsening spinal injury. "
09/01/2012 - "Outcome measures included the following: demographic characteristics, American Spinal Injury Association (ASIA) Impairment Scale (AIS), length of stay (LOS), medical complications, accommodation, support services, continence, mobility and Functional Independence Measure (FIM) motor scores. "
12/01/2010 - "Demographic characteristics, etiology, American Spinal Injury Association (ASIA) impairment scale, functional independence measurement (FIM) subgroup scores, length of stay and medical complications in both groups were compared. "
5. Intensive Care (Surgical Intensive Care)